Pharmacotherapy for Schizophrenia: New Advances
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 22 December 2024 | Viewed by 146
Special Issue Editors
Interests: drugs and schizophrenia; preclinical models of schizophrenia; drugs and novel drug candidates
2. Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
3. Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
Interests: Alzheimer's disease; schizophrenia; depression
Special Issue Information
Dear Colleagues,
Schizophrenia is a severely debilitating psychiatric disorder that still poses significant therapeutic challenges. Progress in pharmacotherapy for schizophrenia has been limited over the past four decades, but several novel therapeutic concepts (NTCs) and compounds are currently emerging. Those NTCs involve the modulation of synaptic strength or synaptic plasticity, the moderation of excessive excitatory or insufficient inhibitory activity, or enhancement of protection against oxidative stress. Improved dopaminergic or serotonergic modulation also still play important roles. Novel compounds include newly developed drugs but also repurposed medication, which may be applied and tested in humans off-label. With such developments, future pharmacotherapeutic strategies envisioned for schizophrenia become increasingly complex, as the potential need for early intervention, patient stratification, combined psycho-social and pharmacological therapy, and precision medicine approaches becomes even more necessary. Significant drivers of the current progress in treatments are new circuit neuroscience techniques in preclinical investigations (like optogenetics, chemogenetics, in vivo imaging and CRISPR/Cas9-mediated genetic modulation), identification and validation of translatable physiological and psychological biomarkers, as well as the use of re-purposable drugs in experimental clinical trials, amongst others.
This Special Issue “Pharmacotherapy in Schizophrenia” welcomes contributions of original research articles or review articles covering those aspects, to illustrate the scope, possibilities, and challenges of future pharmacological treatment of schizophrenia.
Prof. Dr. Dennis Kätzel
Dr. Holger Rosenbrock
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- schizophrenia
- psychosis
- pharmaco-resistance
- refractory symptoms
- cognitive symptoms
- negative symptoms
- aberrant salience
- drug repurposing
- target discovery
- drug development
- translatable biomarkers
- endophenotypes
- precision medicine
- patient stratification
- circuit neuroscience
- glutamate hypothesis
- dopamine hypothesis
- oxidative stress
